序贯T细胞重定向治疗使复发/难治性骨髓瘤患者获得深度且持久缓解
在Mount Sinai医院58例双特异性抗体(BiAb)试验后进展的复发/难治性多发性骨髓瘤(RRMM)患者中,中位年龄67岁、78%伴高危细胞遗传学、中位6线既往治疗。以T细胞重定向作为首次或第二次挽救治疗可行,中位PFS1为28.9个月、PFS2为30.9个月、2年OS为62%。序贯使用不同T细胞重定向治疗可行,可能带来深度且持久的缓解。
要点
- BiAb试验后进展的RRMM患者中,T细胞重定向作为首次或第二次挽救治疗可行。
- 该策略中位PFS1为28.9个月、PFS2为30.9个月、2年OS为62%。
- 序贯使用不同T细胞重定向治疗可能带来深度且持久的缓解。
核心结论
- 序贯使用不同T细胞重定向治疗可行,可能在BiAb治疗后复发的RRMM中带来深度且持久的缓解。
研究设计与样本
- 在Mount Sinai医院识别58例参加BiAb试验后进展的患者,采用Kaplan-Meier法估计PFS1、PFS2和OS。
主要发现
- 患者中位年龄67岁,78%伴高危细胞遗传学,中位6线既往治疗,89%为三类难治,44%为五药难治。
- BiAb试验后中位随访30.5个月,患者接受中位2种额外挽救治疗(范围1-9)。
- 最常见的首次挽救治疗为T细胞重定向,共19例(10例BiAb和9例CAR T细胞)。
- 10例患者将T细胞重定向作为第二次挽救治疗。
- T细胞重定向作为首次或第二次挽救治疗的中位PFS1为28.9个月、PFS2为30.9个月、2年OS为62%。
关键数值与推荐
- T细胞重定向作为首次或第二次挽救治疗的中位PFS1为28.9个月。
- T细胞重定向作为首次或第二次挽救治疗的中位PFS2为30.9个月。
- T细胞重定向作为首次或第二次挽救治疗的2年OS为62%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the approval of 2 CAR T-cell products and numerous BiAb trials. Data on the outcomes after relapse following BiAbs are urgently required to develop strategies for sequencing salvage therapies. We identified 58 patients progressing after a BiAb trial at Mount Sinai Hospital. Progression-free survival (PFS) to the first salvage (PFS1), second salvage therapy (PFS2), and overall survival (OS) were estimated using the Kaplan-Meier method. The median age of the patients was 67 years, and 78% had high-risk cytogenetics. They had a median of 6 prior therapy lines, 89% were triple-class refractory, and 44% were penta-drug refractory. After the BiAb trial, patients were followed for a median of 30.5 months and received a median of 2 additional salvage therapies (range, 1-9). The most common first salvage was T-cell redirection in 19 patients (10 BiAb and 9 CAR T cells). Ten patients underwent T-cell redirection as a second salvage treatment. T-cell redirection therapy as first or second salvage was feasible and associated with a median PFS1 of 28.9 months, PFS2 of 30.9 months, and an OS of 62% at 2 years. The sequential use of different T-cell redirection therapies is possible and may lead to deep and durable responses following the relapse after BiAb therapy in RRMM.
引用
- Mouhieddine TH, Van Oekelen O, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. Blood Adv. 2023. PMID: 36018226. doi:10.1182/bloodadvances.2022007923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。